Aneurysmal subarachnoid hemorrhage. Nontraumatic subarachnoid hemorrhage
Conditions
Interventions
Intervention 1: Intervention group: Nimodipine: 60 mg orally every 4 hours (6 times a day) for 14 days - Cilostazol: 100 mg orally twice a day for 14 days. Intervention 2: Control group: Nimodipine: 6
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with a definitive diagnosis of aneurysmal subarachnoid hemorrhage by a specialist using clinical examinations and imaging Adequate state of alertness (Glasgow Coma Scale = 10) Informed consent of the patient or legal guardian to enter the study
Exclusion criteria
Exclusion criteria: Patients with systemic malignancies, severe renal or hepatic impairment History of allergy to nimodipine or cilostazol and Patients who have contraindications to the study drugs Women during pregnancy or breastfeeding History of previous stroke, severe coagulation disorders, presence of multiple aneurysms requiring simultaneous treatment Diffuse (long axis = 20 mm) or focal (long axis < 20 mm) intracranial hemorrhage with thick clot (short axis = 4 mm) on CT scan performed within 24 hours after intracranial hemorrhage and the clinical grade of patients based on the Hunt and Hess grading system before clipping or coiling should be 1-4
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vasospasm. Timepoint: Three months. Method of measurement: Symptomatic vasospasm, delayed cerebral infarction, neurological sequelae determined by examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMehdi Shafiei
Esfahan University of Medical Sciences
Outcome results
None listed